Masakazu Abé

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Hironobu Hashimoto, Masakazu Abé, Osamu Tokuyama et al. · The Lancet Oncology · 2019 · 235 citations

Medicine, Pharmacology, Pharmacotherapy +16

A novel function of CD82/KAI-1 on E-cadherin-mediated homophilic cellular adhesion of cancer cells

Masakazu Abé, Tsuyoshi Sugiura, Miho Takahashi et al. · Cancer Letters · 2008 · 73 citations

Life Sciences, Cell Biology, Molecular Biology +13

Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial

Masakazu Abé, Yasuyuki Hirashima, Yuka Kasamatsu et al. · Supportive Care in Cancer · 2015 · 69 citations

Medicine, Pharmacology, Pharmacotherapy +16

Suppression of haematopoiesis by IgG autoantibodies from patients with systemic lupus erythematosus (SLE)

H LIU, K Ozaki, Yumi Matsuzaki et al. · Clinical & Experimental Immunology · 1995 · 67 citations

Life Sciences, Hematology, Immunology +15

Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice

Daichi Tamura, Noriaki Jinnouchi, Masakazu Abé et al. · International Journal of Clinical Oncology · 2020 · 47 citations

Medicine, Oncology, Pharmacotherapy +6